Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Riad Salem*, Daneng Li, Nicolas Sommer, Sairy Hernandez, Wendy Verret, Beiying Ding, Riccardo Lencioni

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences